LJM 1993-2820 1819-6357 Libyan Journal of Medicine, Vol. 5, No. 0, June 2010, pp. 1–11 sici xxx PUBMED Abbreviation YousefA.Taher

*Yousef A. Taher, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Al-Fateh Medical University, P.O. Box 83001, Central PostTripoliLibya+218 92 3022980+218 21 4625577

PaulA.J.Henricks AntoonJ.M.van Oosterhout Department of Pharmacology and Clinical Pharmacy Faculty of Pharmacy, Al-Fateh Medical University

TripoliLibya

Department of Pharmacology and Pathophysiology Utrecht Institute for Pharmaceutical Sciences Utrecht University

UtrechtThe Netherlands

Laboratory of Allergology and Pulmonary Diseases University Medical Center Groningen, Groningen University

GroningenThe Netherlands

Libyan Journal of Medicine REVIEW ARTICLE Immunotherapy in allergic asthma Allergic asthma is a disease characterized by persistent allergen-driven airway inflammation, remodeling, and airway hyperresponsiveness. CD4⁺ T-cells, especially T-helper type 2 cells, play a critical role in orchestrating the disease process through the release of the cytokines IL-4, IL-5, and IL-13. Allergen-specific immunotherapy (SIT) is currently the only treatment with a long-term effect via modifying the natural course of allergy by interfering with the underlying immunological mechanisms. However, although SIT is effective in allergic rhinitis and insect venom allergy, in allergic asthma it seldom results in complete alleviation of the symptoms. Improvement of SIT is needed to enhance its efficacy in asthmatic patients. Herein, the immunoregulatory mechanisms underlying the beneficial effects of SIT are discussed with the ultimate aim to improve its treatment efficacy. allergic asthma immunotherapy dendritic cell regulatory T cells Th2 lymphocytes hyperresponsiveness eosinophilia IgE IL-10 Allergic asthma is recognized as a chronic inflammatory disease of the airways in which many types of cells play a role, in particular mast cells, eosinophils, B- and T-lymphocytes, and epithelial cells. It is characterized by the production of allergen-specific immunoglobulin (Ig)E antibodies, reversible airflow obstruction, airway hyperresponsiveness (AHR) to a wide variety of specific or non-specific stimuli, chronic airway inflammation, and airway remodeling 1. During the past several decades, the prevalence of allergic asthma is increasing dramatically (> 20% in every 10 years), especially in children 2. Approximately, it affects 10–15% of the population in most developed industrial countries 2. Both genetic and environmental factors are involved in allergic asthma. Genetic studies indicate that multiple genes are linked to the onset of this disease 345. However, the epidemic increase of asthma cannot be explained by genetic changes in the population. Changes in environment and lifestyle including isolation of houses which increases numbers of house dust mite, and childhood immunizations have contributed to the increase 6789. In addition, epidemiological and clinical studies have suggested a link between the relative decreased exposure to bacteria or other pathogenic agents (such as helminthes) during the first years of life, and the increase in allergic asthma 101112; this is referred to as the ‘hygiene hypothesis.’ The concepts of the pathogenesis of allergic asthma are illustrated in Fig. 1. The development of allergic asthma requires sensitization to an environmental allergen, which can occurs years before the onset of clinical symptoms 613. For allergic sensitization allergens are taken up and processed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs) and presented to allergen-specific T-cells that subsequently differentiate into T-helper (Th) 2-type cells. Activation of Th2 cells leads to the production of inflammatory cytokines, such as interleukin 4 (IL-4) and IL-13, thereby stimulating allergen-specific B-cells to proliferate and switch to production of IgE 1415. Then IgE binds to high-affinity IgE receptor FcϵRI on mast cells. Upon re-exposure, the allergen will bind to allergen-specific IgE on mast cells thereby cross-linking the IgE–FcϵRI complexes which subsequently cause the release of preformed mediators like histamine and several other inflammatory mediators 1617. These mast cell-derived mediators cause the early asthmatic reaction which is characterized by airway smooth muscle constriction, extensive vascular leakage, mucus hypersecretion, enhanced airway responsiveness, and recruitment of inflammatory cells 171819.

Schematic representation of the pathophysiology of allergic asthma. In genetically predisposed individuals, primary exposure to an allergen leads to activation of Th2 lymphocytes and stimulation of IgE synthesis. Later on, exposure causes immediate release of the biologically active mediators (histamine, leukotrienes) via mast cell degranulation and further activation of Th2 cells with resulting eosinophil inflammation and AHR.

In approximately 50% of the asthmatic patients this early phase reaction is followed by the late phase reaction. This phase is characterized by significant involvement of infiltrated inflammatory cells, such as eosinophils, T lymphocytes and macrophages, and resident epithelial, endothelial and smooth muscle cells in promoting the chronic symptoms of airway inflammation. In addition, these cells may also be an important source of inflammatory mediators like chemokines, cytokines, and leukotrienes in asthma. CD4⁺ T-cells play a crucial role in controlling inflammation in allergic asthma. They are the predominant lymphocyte population that infiltrates the airways in asthmatics and are activated in these sites, expressing the surface activation markers class II histocompatibility antigen [HLA-DR], CD25 (IL-2R), and very late activation antigen-1 (VLA-1) 2021. In addition to CD4⁺ T-cells, CD8⁺ T-cells, and &ggr;/&dgr; T-cells have been identified in the airways of allergic asthmatics 21. About 60% of the CD4⁺ T-cells in the airway of persons with asthma are invariant natural killer T (iNKT) cells 22232425. However, there is still controversy whether iNKT-cells can induce allergic asthma in the absence of CD4⁺ T-cells 262728.Human and murine CD4⁺ T-cells are divided into two broad functional subsets according to their profiles of cytokine secretion 2930. The conditions under which CD4⁺ Th cells become activated during an immune response determine the development toward the Th1- or the Th2-phenotype 31. CD4⁺ Th1-type cells secrete predominantly IL-2 and interferon gamma (IFN-&ggr;) and are particularly implicated in cell-mediated immune responses against invading intracellular pathogens, such as viruses 3233. CD4⁺ Th2-type cells produce a different panel of cytokines including IL-4, IL-13, and IL-5 34. IL-4 promotes the development of Th2 cells and together with other cytokines, promotes the growth of mast cells, basophils, and eosinophils 3536. Furthermore, IL-4 and IL-13 are required for the induction of proliferation and isotype switching to IgE by B-cells that recognize the allergen 1437. IL-5 secretion by Th2 cells is critical for eosinophil differentiation and maturation 3839.Over the years it became clear that the allergen-induced airway inflammation is orchestrated by activated Th2 cells. Th2-type lymphocytes play a critical role in the initiation, progression, and persistence of allergic asthma. Initially, a disturbed balance between Th1- and Th2-mediated immune responses has been postulated to underlie aberrant Th2 reactions to ‘innocuous’ environmental antigens. Indeed, allergen-specific T-cell clones isolated from the blood of allergic individuals express a Th2 cytokine profile secreting IL-4, IL-5, and minimal IFN-&ggr; and IL-2, whereas those clones from non-atopic individuals displayed a Th1 profile 40. Furthermore, allergic asthma is associated with the expression of IL-3, IL-4, and IL-5 in bronchoalveolar cells, strongly supporting Th2 activation 41. Moreover, it has been shown that when antigen-specific Th2 cells activated with inhaled antigen, Th2 cells-induced airway eosinophilia, mucus hypersecretion, and AHR after short-exposure to antigen, while Th1 cells resulted in a neutrophil-predominant inflammatory response without mucus production or AHR 4243, indicating that Th1 cells alone do not produce any of the characteristic features of asthma. In human studies, CD4⁺ T-cells producing IL-4, IL-5, and IL-13 have been identified in bronchoalveolar lavage fluid and airway biopsies from asthmatics patients. These cytokines are secreted in the airways of patients with mild or asymptomatic disease 41. Furthermore, it has been shown that CD4⁺ Th2 lymphocytes are increased in the airways of asthmatic patients after antigen challenge 214445. Current pharmacologic therapies for allergic asthma, such as bronchodilators and inhaled corticosteroids, are effective in reducing and preventing symptom development, but do not reverse the progression of or cure this disease. SIT is unique in that it not only reduces symptoms, but also induces long-lasting disease remission. SIT has been shown to improve allergic dysfunction and to re-direct the immune system away from the allergic response.SIT was first introduced at St. Mary's Hospital London, at the end of the nineteenth century and many of the basic principles described remain valid today. In 1911, Noon carried out the first study of active immunization to prevent allergy against grass pollen using s.c. injection of a distilled water extract of the pollen of timothy grass, Phleum pretense 46. In 1918, it was generally accepted that hay fever, asthma, and anaphylaxis were the result from antibodies produced after exposure to sensitizing antigen 47.By 1961, a new technique was developed to allow in vitro measurements of histamine release from cells in whole blood in the presence of specific allergen before and after treatment with ragweed extract 48. The findings demonstrated that after SIT, histamine release was completely abolished in a few patients and was reduced in others. Five years later, a double-blind study performed by Lichtenstein and Osler 49 demonstrated that the treatment with crude ragweed extract or the major allergen of ragweed ‘Amb a 1’ resulted in reduction of cellular sensitivity in some patients. Treated patients showed little correlation between cellular sensitivity and symptom scores. This finding was accompanied with a rise in blocking antibodies. After these results, the term immunotherapy has been used to describe the process because it greatly deals with complex immunologic changes. SIT for the management of allergic asthma continues to be a matter for discussion 50515253. Abramson and colleagues 515455 performed a meta-analysis of all trials published over the past 50 years of the twentieth century examining the impact of SIT in patients with allergic asthma. Overall, SIT was efficacious of decreasing asthma medication use, reducing bronchial hyperresponsiveness, and improving asthma symptom scores. While there was no consistent effect on lung function, SIT significantly reduced the airways response to inhalation of specific allergen, with some reduction in non-specific AHR as well. The potential mechanisms that have been proposed to explain the beneficial effects of SIT are illustrated in Fig. 2.

Schematic representation of the potential immune deviation leading to the beneficial effects of SIT. Allergen SIT results in both a shift in allergen-specific T-cells from Th2 to Th0/Th1 responses and the generation of IL-10 and TGF-&bgr; producing T regulatory (Treg) cells. Allergen-specific Th1 immune responses protect against the development of allergic disorders by inducing the production of IFN-&ggr;, which inhibits the development of Th2 cells. The regulatory cytokines IL-10 and TGF-&bgr; induce switching of B cell responses in favor of IgG4 antibodies and IgA antibodies, respectively, and suppress IgE production. IL-10 and TGF-&bgr; directly or indirectly suppress effector cells of allergic inflammation such as mast cells and eosinophils thereby preventing release of mediators and late-phase inflammation. Sold gray arrows represent immune response pathway to natural exposure; dotted arrows represent immune response pathway to IT; blocked lines represent inhibition.

To explain the immunological mechanisms underlying the clinical improvement, intensive research has concentrated upon the specific antibody response in serum with respect to class and subclass distribution 56. Studies showed that the allergen-specific IgE levels rise temporarily during initial phase of SIT, but fall back to pre-treatment levels during maintenance therapy 57. Subsequently, it was demonstrated that SIT also induces allergen-specific IgG (mostly IgG1 and IgG4) and in few reported cases IgA levels 585960. These findings led to the hypotheses that these IgG antibodies contribute to the immunosuppressive effects of SIT by blocking IgE-facilitated antigen presentation 6162 and that such antibodies act as blocking antibodies by engaging low-affinity Fc receptors for Ig (e.g. Fc&ggr;RII) expressed by B lymphocytes, basophils, and mast cells 60. In fact, a substantial number of studies demonstrated increased specific IgG4 levels together with clinical improvement 6364. However, the role of IgG (and IgA) in SIT has been questioned and it is not clear whether the significant increase in IgG levels has a causal role in alleviating symptoms or simply represents a bystander effect, occurring as a consequence of high allergen exposure. In Fc&ggr; knockout mouse model of allergic asthma we found that bronchoalveolar lavage (BAL) eosinophilia, Th2 cytokines, and serum ovalbumin (OVA)-specific IgE levels were strongly suppressed by SIT, demonstrating that IgG Fc&ggr; receptors have no major role in the beneficial effects of SIT (unpublished data). Moreover, results demonstrated that the suppression of allergen-induced airway inflammation by SIT is not B-cell dependent, ruling out a critical role for B-cells, IgGs, and IgA in SIT in the mouse model of allergic asthma.Thus, in the context of allergic diseases, including asthma, most research indicates that during SIT the increase of IgG is an epiphenomenon, however, the role of allergen-specific antibodies, as putative ‘blocking factors(s),’ in SIT providing protection against allergic disease appears unlikely. The generation of an effective immune response involves antigen-specific T-cell expansion and differentiation of effector function. T-cell activation requires at least two distinct signals, including signaling via the antigen-specific T-cell receptor and a co-stimulatory pathway 31. Antigen stimulation of T-cells can lead either to a positive immune response, characterized by proliferation, differentiation, clonal expansion, and effector function, or in the absence of an appropriate co-stimulatory signal to a state of long-lasting unresponsiveness, termed anergy 65. The most important co-stimulatory molecules involved are CD28/CD152 (CTLA-4)–CD80/CD86 (B7-1/-2) and CD40-CD154 (CD40 ligand) 666768. Anergy induction can down-regulate both cellular and humoral immune responses. The induction of T-cell non-responsiveness or anergy as the mechanism of SIT is supported by the observed diminution of allergen-specific T-cell proliferation and cytokine production 69, although in some instances IL-2 was able to restore these functions 70. However, the usually increased IgG production during SIT cannot be explained by the induction of T-cell anergy 7172. Various methods for anergy induction have been described. Stimulation of T-cells with high doses of antigen in the absence of appropriate co-stimulation or in the presence of IL-10 has been found to induce a profound form of anergy 7374. Under these conditions anergic T-cells showed limited peripheral expansion and a significant amount of death, with a residual subset of cells remaining that were unresponsive to antigen restimulation both in vivo and in vitro. It has been suggested that T-cells rendered anergic in vivo and in vitro become regulatory T-cells that can regulate other T-cell responses 7576. In the late 1980s, a favorable explanation was based on the Th1/Th2 dichotomy in specific immune reactions 29. Mechanistic studies demonstrated that SIT alters the balance of cytokines released from Th-lymphocytes with a shift from Th2-cells in association with allergic inflammation toward Th1-cells that release IFN-&ggr;, which inhibits Th2-cells 777879. Early studies showed that allergen-specific T-cell clones shift from IL-4 to IFN-&ggr; production after SIT 7780. However, the effects of SIT on Th1 cytokine secretion are less consistent 81. In humans, several clinical trials demonstrated a reduction of the allergen-specific Th2 response, whereas the Th1 response remained undetectable 7882 and in a separate study, SIT diminished both allergen-specific Th2 and Th1 responses 83. In experimental allergic asthma models some studies have confirmed that the relation between presence of Th1-associated cytokines and amelioration of disease, but others have not found such effects 84. In recent years, the concept of immune deviation toward Th1 response by SIT lost favor with the alternative observation on regulatory T-cells.Adaptive regulatory T (Treg) cells are taking the center stage as crucial immunoregulatory cells that may offer an explanation for many of the observations that occur during SIT that cannot be adequately explained by the Th2 to Th1 shift 858687. Several subsets of regulatory T-cells with distinct phenotypes and mechanism of actions have been identified. These include: 1 naturally occurring CD4⁺CD25⁺Foxp3⁺ T-cells (nTregs) that inhibit immune responses through cell-to-cell contact, 2 CD4⁺Foxp3⁺ iTregs induced in the periphery, in contrast to nTregs not generated in the thymus; the capacity of these cells to suppress the proliferation of naïve T-cells requires cell–cell contact, and 3 cells induced in the periphery following antigen exposure (aTreg cells). aTreg cells are subdivided into type 1 regulatory T (Tr1) cells which secrete high levels of IL-10 and low to moderate levels of transforming growth factor (TGF)-&bgr; and type 3 regulatory T (Th3) cells which secrete TGF-&bgr;. The natural CD4⁺CD25⁺Foxp3⁺ regulatory T (nTreg) cells are generated in the thymus and represent 5–10% of the CD4⁺ T lymphocytes both in mice and humans. These cells are thought to perform a specialized role in controlling both the innate and the adaptive immune response 8889. Depletion of nTreg cells leads to the spontaneous development of various autoimmune diseases 90919293949596. Although the mechanism of immune regulation mediated by nTreg cells is not well understood, these cells can both directly suppress responding T-cells and down-modulate APC function in vitro 9798. nTreg cells may also convert CD4⁺ Th cell into regulatory cells expressing IL-10 and/or TGF-&bgr; in culture systems 99100. It has been shown that nTreg cells induce infectious tolerance in vivo by catalyzing the formation of IL-10 producing regulatory T-cells 101. In recent years, it has been demonstrated that SIT is associated with the induction of aTreg cells. The aTreg cells are generated in the periphery from naïve T-cells after encountering antigens presented by tolerogenic DCs. In studies of SIT for bee venom anaphylaxis, Akdis et al. 85 were the first to provide evidence for a role of IL-10 and Tr1 cells in the beneficial effects of SIT. They observed that the therapy-induced increase in secretion of IL-10 in T-cell cultures along with decreased allergen-driven proliferation and decreased production of Th2 and Th1 cytokines. Moreover, in clinical trials, SIT has been shown to increase the production of IL-10 by APCs, including B cells, monocytes, and macrophages 6187102. Findings were extended by SIT studies with airborne allergens that showed increases in IL-10 and TGF-&bgr; producing antigen-specific Treg cells in the blood and airway tissue 61858687. Induction of IL-10 producing Tr1 cells has been shown to be associated with successful SIT 8586. Animal studies confirmed the suppressive role of IL-10 during allergic inflammatory diseases 84103104105106. In human studies, the regulatory cytokine IL-10 has been shown to increase the production of IgG4 while preventing IL-4-mediated class switching to IgE 107. Furthermore, IL-10 down-regulate IgE-dependent activation of basophils and mast cells, and decrease survival and activation of eosinophils 108. In addition, IL-10 (and TGF-&bgr;) might act on APCs. IL-10 down-regulates Major Histocompatability Complex (MHC) class II expression on monocytes and reduces their antigen presentation capacity 109. Moreover, IL-10 down-regulates the CD80 expression on DCs and macrophages 110111. IL-10 may therefore block the APC dependent CD28–CD80 interaction and subsequent co-stimulatory signaling in T-cells 112.The other immunoregulatory cytokine associated with regulatory T-cells is TGF-&bgr;. Studies have provided evidence for increases in the amount of TGF-&bgr;-driven allergen-specific IgA following SIT, indicating other antibody classes than IgG might contribute to clinical efficacy 87. Moreover, TGF-&bgr; has been shown to induce the expression of IL-10 by T-cells 113. Literature data suggest that early increase in IL-10 85 and sustained TGF-&bgr; production may be required for successful SIT to induce stable tolerance to non-pathogenic environmental antigens 114. Although there is suggestive evidence that SIT achieves beneficial effectiveness by the induction of aTreg cells, the mechanism by which SIT induces aTreg cells is not completely understood. Over the past decade, it has become clear that DCs play a critical role in the generation of all aTreg cell subsets 115 and regulation of immune responses to a variety of antigens 116. The ability of DCs to induce immunity or tolerance depends on their maturation state. Tolerogenic DCs are semi-mature cells with increased expression of MHC II and CD86 but low levels of expression of CD40 and absence of the pro-inflammatory cytokines IL-6 and TNF-&agr; 117. It has been shown that aTreg cells induced by immature DCs are characterized by high levels of IL-10 cytokine secretion 118119. The nuclear factor-&kgr;B (NF-&kgr;B) protein Re1B activity is critically required for DCs maturation 120. Re1B-deficient bone marrow-derived DCs (BMDCs) or BMDCs in which Re1B activity is inhibited have the potential to induce antigen-specific immune tolerance in vivo 121. Inhibition of NF-&kgr;B signaling by various drugs 122123124 induces DCs to acquire tolerogenic properties that favor the induction of Tr1-like cells in vitro and tolerance in mouse models of transplantation and autoimmune diseases 125126127.Besides this, recent findings demonstrate that DCs induce development of aTreg cells by several mechanisms including high expression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) 128129. IDO expressing DCs inhibit T-cell proliferation in vitro and promote tolerance in vivo 130131, including maternal tolerance during pregnancy 132, control of allograft rejection 133, and protection against autoimmunity 134. A number of studies have also demonstrated that IDO is implicated in tolerance induction by regulatory T-cells expressing cytotoxic T-lymphocyte antigen-4 (CTLA-4) 135136. Moreover, IDO may directly mediate inhibition of T-cells proliferation by tryptophan depletion or downstream tryptophan metabolites 137138. Recently, we showed that inhibition of IDO throughout SIT abrogated the efficacy of SIT on the reduction of BAL eosinophil numbers and AHR to methacholine, but no changes in serum OVA-specific IgE levels were observed 139. In addition, we demonstrated that inhibition of IDO throughout the aerosol challenge period did not interfere with tolerance induction by SIT. These findings reveal that IDO plays a role only during induction of tolerance by SIT and that activity of IDO is irrelevant for the effects of SIT thereafter. Moreover, considering the conceptual possibilities that either tryptophan depletion or downstream tryptophan metabolites mediated-IDO immunoregulation we showed that formation of tryptophan metabolites, rather than tryptophan depletion, is the mechanism by which SIT induces tolerance to the induction of airway manifestations of asthma. The goal of SIT is the transformation of an allergic individual into one who can tolerate allergen exposure by converting deleterious allergic immune response into protective responses. Despite the impressive efficacy of allergen (injection) SIT for treatment of allergic rhinitis and insect venom allergy, its efficacy in allergic asthma remains controversial 51. Furthermore, it has been reported that s.c. administration of allergens can induce severe systemic reactions due to cross-linking of allergen-specific IgE on mast cells 140141. Thus, for development of a more effective and safe form of SIT, more insight into the underlying immunological mechanisms of allergen IT is considered necessary to improve efficacy, in particular in asthmatic patients. There is growing evidence that the positive effects of SIT are associated with aTreg cells (Tr1 and Th3) and the immunosuppressive cytokines that they produce. The mechanisms by which these cells are induced by SIT are still not fully understood. Well-described pathways to induce aTreg cells are antigen presentation to T-cell by immature DCs or the presence of IL-10 or TGF-&bgr; in the local microenvironment. In this regard, combination of SIT with administration of compounds that inhibit DCs maturation, such as the biologically active form of vitamin D₃ (1&agr;,25-dihydroxyvitamin D₃) or glucocorticoids, might be novel immunotherapeutic strategies to improve SIT for better treatment of allergic diseases, including allergic asthma. Interestingly, in a mouse model of allergen immunotherapy, we recently demonstrated that co-administration of 1&agr;,25-dihydroxyvitamin D₃ effectively suppressed AHR to methacholine and potentiated the reduction of serum allergen-specific IgE levels and BAL eosinophilia in the suboptimal SIT regime matched by a reduction in Th2 cytokines, IL-5, and IL-13 142. We further observed that in vitro antigen-induced productions of Th2-cytokines are decreased in lung-draining lymph node cells after this combination SIT. Moreover, data demonstrates that the immunoregulatory cytokines IL-10 and TGF-&bgr; are involved in tolerance to allergen-induced airway manifestation of asthma since the suppressive effects of combined SIT are completely abrogated by blocking of the IL-10R and neutralizing of TGF-&bgr; by using mAbs at the time of antigen inhalation challenge. Peripheral (naturally occurring and adaptive) T- cell tolerance is the key immunological mechanism in healthy immune response to self- and non-infectious non-self-antigen. Changes in the balance between allergen-specific Treg and Th2, and/or Th1 cells are very crucial in the development and also treatment of allergic diseases. Understanding of the immunological mechanisms that lead to tolerance induction by SIT, Fig. 3, in particular the role of regulatory T-cells in allergen-specific peripheral tolerance may lead to more rational and safer approaches that could result in prevention and cure of allergic diseases, including asthma.

Hypothetical scheme of the proposed mechanisms contributing to the induction of tolerance by SIT. (A) Natural exposure to an allergen leads to activation of Th2 cells. (B) nTreg cells are generated in thymus, but can also develop from conventional CD4⁺ T-cells by specific condition or signals. nTreg cells induce IDO expression on dendritic cell (IDO⁺DC). This is partially mediated via the interaction of CTLA-4 expressed on nTreg and CD80 (B7) expressed on DC. (C) IDO catalyzes the initial and rate-limiting step of tryptophan degradation. (D) IDO expressing DC induces development of Treg after allergen IT by a mechanism at present not completely defined. (E) 1,25(OH)₂D₃ inhibits transcription factor NF-&kgr;B thereby inhibiting maturation of DC and resulting in tolerogenic DC, which direct the induction of Treg cells. Treg cells suppressed Th2 responses and effector cells by the release of immunoregulatory cytokines IL-10 and TGF-&bgr;. (F) The role of allergen-specific IgA is unclear. Dotted arrows represent immune response pathway to SIT; blocked lines represent inhibition.

Y.A.T was supported by a grant 965.02 from the Libyan Ministry of Higher Education This study was partly financially supported by the Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. MaddoxLSchwartzDA. The pathophysiology of asthma Annu Rev Med. 200253 47798 EUROP WHO. Environmental hazards trigger childhood allergic disorders. Fact sheet EURO/01/3. April 2003. BosseYHudsonTJ. Toward a comprehensive set of asthma susceptibility genes Annu Rev Med. 200758 17184 CarrollW. Asthma genetics: pitfalls and triumphs Paediatr Respir Rev. 20056 6874 CooksonWO. Asthma genetics Chest 2002121 S7S13 HoltPGThomasWR. Sensitization to airborne environmental allergens: unresolved issues Nat Immunol. 20056 95760 PerryTTWoodRAMatsuiECCurtin-BrosnanJRandCEgglestonPA. Room-specific characteristics of suburban homes as predictors of indoor allergen concentrations Ann Allergy Asthma Immunol. 200697 62835 TrasandeLThurstonGD. The role of air pollution in asthma and other pediatric morbidities J Allergy Clin Immunol. 2005115 68999 von MutiusE. The environmental predictors of allergic disease J Allergy Clin Immunol. 2000105 919 MatricardiPMRosminiFRiondinoSFortiniMFerrignoLRapicettaM Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study BMJ 2000320 4127 TantisiraKGWeissST. Childhood infections and asthma: at the crossroads of the hygiene and Barker hypotheses Respir Res. 20012 3247 StrachanDP. Family size, infection and atopy: the first decade of the “hygiene hypothesis” Thorax 200055 S210 NoertjojoKDimich-WardHObataHManfredaJChan-YeungM. Exposure and sensitization to cat dander: asthma and asthma-like symptoms among adults J Allergy Clin Immunol. 1999103 605 Del PreteGMaggiEParronchiPChretienITiriAMacchiaD IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants J Immunol. 1988140 41938 Van der Pouw KraanTCVan der ZeeJSBoeijeLCDe GrootERStapelSOAardenLA. The role of IL-13 in IgE synthesis by allergic asthma patients Clin Exp Immunol. 1998111 12935 HartPH. Regulation of the inflammatory response in asthma by mast cell products Immunol Cell Biol. 200179 14953 DurhamSR. Mechanisms of mucosal inflammation in the nose and lungs Clin Exp Allergy. 199828 116 CharlesworthEN. Late-phase inflammation: influence on morbidity J Allergy Clin Immunol. 199698 S2917 BraddingPHolgateST. Immunopathology and human mast cell cytokines Crit Rev Oncol Hematol. 199931 11933 CorriganCJHartnellAKayAB. T lymphocyte activation in acute severe asthma Lancet 19881 112932 WalkerCBodeEBoerLHanselTTBlaserKVirchowJCJr Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage Am Rev Respir Dis. 1992146 10915 AkbariOFaulJLHoyteEGBerryGJWahlstromJKronenbergM CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma N Engl J Med. 2006354 111729 AkbariOStockPMeyerEKronenbergMSidobreSNakayamaT Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity Nat Med. 20039 5828 BilenkiLYangJFanYWangSYangX. Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production Eur J Immunol. 200434 34554 LisbonneMDiemSde Castro KellerALefortJAraujoLMHachemP Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model J Immunol. 2003171 163741 DasJEynottPJuppRBothwellAVan KaerLShiY Natural killer T cells and CD8(+) T cells are dispensable for T cell-dependent allergic airway inflammation Nat Med. 200612 13456 MutalithasKCroudaceJGuillenCSiddiquiSThickettDWardlawA Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma J Allergy Clin Immunol. 2007119 12746 VijayanandPSeumoisGPickardCPowellRMAngcoGSammutD Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease N Engl J Med. 2007356 141022 MosmannTRCoffmanRL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties Annu Rev Immunol. 19897 14573 WierengaEASnoekMJansenHMBosJDvan LierRAKapsenbergML. Human atopen-specific types 1 and 2 T helper cell clones J Immunol. 1991147 29429 KapsenbergMLHilkensCMWierengaEAKalinskiP. The role of antigen-presenting cells in the regulation of allergen-specific T cell responses Curr Opin Immunol. 199810 60713 PintoRAArredondoSMBonoMRGaggeroAADiazPV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol Pediatrics 2006117 e87886 JohnsonPAConwayMADalyJNicolsonCRobertsonJMillsKH. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses J Gen Virol. 200081 173745 MosmannTRCherwinskiHBondMWGiedlinMACoffmanRL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins J Immunol. 1986136 234857 SwainSLWeinbergADEnglishMHustonG. IL-4 directs the development of Th2-like helper effectors J Immunol. 1990145 3796806 CoyleAJLe GrosGBertrandCTsuyukiSHeusserCHKopfM Interleukin-4 is required for the induction of lung Th2 mucosal immunity Am J Respir Cell Mol Biol. 199513 549 BarnerMMohrsMBrombacherFKopfM. Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses Curr Biol. 19988 66972 CoffmanRLSeymourBWHudakSJacksonJRennickD. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice Science 1989245 30810 StaffordSLowellCSurSAlamR. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation J Immunol. 2002168 197883 KapsenbergMLJansenHMBosJDWierengaEA. Role of type 1 and type 2 T helper cells in allergic diseases Curr Opin Immunol. 19924 78893 RobinsonDSHamidQYingSTsicopoulosABarkansJBentleyAM Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma N Engl J Med. 1992326 298304 CohnLHomerRJMarinovARankinJBottomlyK. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production J Exp Med. 1997186 173747 CohnLTepperJSBottomlyK. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells J Immunol. 1998161 38136 AzzawiMBradleyBJefferyPKFrewAJWardlawAJKnowlesG Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma Am Rev Respir Dis. 1990142 140713 CorriganCJKayAB. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status Am Rev Respir Dis. 1990141 9707 NoonL. Prophylactic inoculation against hay fever Lancet 19112 15723 CookeR. Hay fever and asthma: the uses and limitations of desensitization NY Med J. 1918107 57783 ArsdelPJVMiddletonEJ. the effect of hyposensitization on the in vitro histamine release by specific antigen J Allergy. 196132 34856 LichtensteinLMOslerAG. Studies on the mechanisms of hypersensitivity phenomena. XII. An in vitro study of the reaction between ragweed pollen antigen, allergic human serum and ragweed-sensitive human leukocytes J Immunol. 196696 16979 BousquetJMichelFB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol. 199494 111 AbramsonMJPuyRMWeinerJM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials Am J Respir Crit Care Med. 1995151 96974 Bousquet J. Pro: immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med. 2001; 164: 2139–40. (Discussion 41–2) Adkinson NF Jr . Con: immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med. 2001; 164: 2140–1. (Discussion 1–2) AbramsonMPuyRWeinerJ. Immunotherapy in asthma: an updated systematic review Allergy 199954 102241 Abramson MJ , Puy RM , Weiner JM . Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2000; CD001186. DjurupR. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy Allergy 198540 46986 CreticosPSVan MetreTEMardineyMRRosenbergGLNormanPSAdkinsonNFJr Dose response of IgE and IgG antibodies during ragweed immunotherapy J Allergy Clin Immunol. 198473 94104 GehlharKSchlaakMBeckerWBufeA. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome Clin Exp Allergy. 199929 497506 JakobsenCGBodtgerUPoulsenLKRoggenEL. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance Clin Exp Allergy. 200535 1938 WachholzPADurhamSR. Induction of ‘blocking’ IgG antibodies during immunotherapy Clin Exp Allergy. 200333 11714 Nouri-AriaKTWachholzPAFrancisJNJacobsonMRWalkerSMWilcockLK Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity J Immunol. 2004172 32529 van NeervenRJWikborgTLundGJacobsenBBrinch-NielsenAArnvedJ Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation J Immunol. 1999163 294452 FlickerSValentaR. Renaissance of the blocking antibody concept in type I allergy Int Arch Allergy Immunol. 2003132 1324 WachholzPADurhamSR. Mechanisms of immunotherapy: IgG revisited Curr Opin Allergy Clin Immunol. 20044 3138 GudmundsdottirHTurkaLA. T cell costimulatory blockade: new therapies for transplant rejection J Am Soc Nephrol. 199910 135665 GaoJXMadrenasJZengWCameronMJZhangZWangJJ CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection Immunology 199998 15970 KobataTAzumaMYagitaHOkumuraK. Role of costimulatory molecules in autoimmunity Rev Immunogenet. 20002 7480 WellsADWalshMCBluestoneJATurkaLA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy J Clin Invest. 2001108 895903 EbnerCSiemannUBohleBWillheimMWiedermannUSchenkS Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl a major grass pollen allergen Clin Exp Allergy. 199727 100715 MoverareRElfmanLBjornssonEStalenheimG. Cytokine production by peripheral blood mononuclear cells following birch-pollen immunotherapy Immunol Lett. 200073 516 BahcecilerNNIsikUBarlanIBBasaranMM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study Pediatr Pulmonol. 200132 4955 PajnoGBBarberioGDe LucaFMorabitoLParmianiS. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study Clin Exp Allergy. 200131 13927 JenkinsMKSchwartzRH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo J Exp Med. 1987165 30219 SchwartzRH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med. 1996184 18 BuerJLanoueAFranzkeAGarciaCvon BoehmerHSarukhanA. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo J Exp Med. 1998187 17783 TaamsLSvan RensenAJPoelenMCvan ElsCABesselingACWagenaarJP Anergic T cells actively suppress T cell responses via the antigen-presenting cell Eur J Immunol. 199828 290212 JutelMPichlerWJSkrbicDUrwylerADahindenCMullerUR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures J Immunol. 1995154 418794 SecristHChelenCJWenYMarshallJDUmetsuDT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals J Exp Med. 1993178 212330 VarneyVAHamidQAGagaMYingSJacobsonMFrewAJ Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses J Clin Invest. 199392 64451 McHughSMDeightonJStewartAGLachmannPJEwanPW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy Clin Exp Allergy. 199525 82838 KowalskiMLJutelM. Mechanisms of specific immunotherapy of allergic diseases Allergy 199853 48592 O'BrienRMByronKAVarigosGAThomasWR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes Clin Exp Allergy. 199727 4651 AkdisCAAkdisMBleskenTWymannDAlkanSSMullerU Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro J Clin Invest. 199698 167683 VissersJLvan EschBCHofmanGAKapsenbergMLWellerFRvan OosterhoutAJ. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model J Allergy Clin Immunol. 2004113 120410 AkdisCABleskenTAkdisMWuthrichBBlaserK. Role of interleukin 10 in specific immunotherapy J Clin Invest. 1998102 98106 FrancisJNTillSJDurhamSR. Induction of IL-10 + CD4 + CD25+ T cells by grass pollen immunotherapy J Allergy Clin Immunol. 2003111 125561 JutelMAkdisMBudakFAebischer-CasaultaCWrzyszczMBlaserK IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy Eur J Immunol. 200333 120514 MaloyKJSalaunLCahillRDouganGSaundersNJPowrieF. CD4 + CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms J Exp Med. 2003197 1119 SakaguchiSSakaguchiNShimizuJYamazakiSSakihamaTItohM Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance Immunol Rev. 2001182 1832 Suri-PayerEAmarAZThorntonAMShevachEM. CD4 + CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells J Immunol. 1998160 12128 SakaguchiSSakaguchiNAsanoMItohMTodaM. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases J Immunol. 1995155 115164 BrunkowMEJefferyEWHjerrildKAPaeperBClarkLBYasaykoSA Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse Nat Genet. 200127 6873 FontenotJDGavinMARudenskyAY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells Nat Immunol. 20034 3306 KhattriRCoxTYasaykoSARamsdellF. An essential role for Scurfin in CD4 + CD25+ T regulatory cells Nat Immunol. 20034 33742 WildinRSRamsdellFPeakeJFaravelliFCasanovaJLBuistN X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy Nat Genet. 200127 1820 ZieglerSF. FOXP3: of mice and men Annu Rev Immunol. 200624 20926 CederbomLHallHIvarsF. CD4 + CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells Eur J Immunol. 200030 153843 ThorntonAMShevachEM. CD4 + CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production J Exp Med. 1998188 28796 JonuleitHSchmittEKakirmanHStassenMKnopJEnkAH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells J Exp Med. 2002196 25560 ZhengSGWangJHGrayJDSoucierHHorwitzDA. Natural and induced CD4 + CD25+ cells educate CD4 + CD25-cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10 J Immunol. 2004172 521321 MekalaDJAlliRSGeigerTL. IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4 + CD25+ T lymphocytes Proc Natl Acad Sci USA. 2005102 1181722 AkdisCABlaserK. Role of IL-10 in allergen-specific immunotherapy and normal response to allergens Microbes Infect. 20013 8918 GrunigGCorryDBLeachMWSeymourBWKurupVPRennickDM. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis J Exp Med. 1997185 108999 Zuany-AmorimCHaileSLeducDDumareyCHuerreMVargaftigBB Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice J Clin Invest. 199595 264451 HagenbaughASharmaSDubinettSMWeiSHArandaRCheroutreH Altered immune responses in interleukin 10 transgenic mice J Exp Med. 1997185 210110 Van OosterhoutAJVan EschBHofmanGHofstraCLVan ArkINijkampFP Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma Am J Respir Cell Mol Biol. 199819 6228 JeanninPLecoanetSDelnesteYGauchatJFBonnefoyJY. IgE versus IgG4 production can be differentially regulated by IL-10 J Immunol. 1998160 355561 RoyerBVaradaradjalouSSaasPGuillossonJJKantelipJPArockM. Inhibition of IgE-induced activation of human mast cells by IL-10 Clin Exp Allergy. 200131 694704 de Waal MalefytRHaanenJSpitsHRoncaroloMGte VeldeAFigdorC Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression J Exp Med. 1991174 91524 DingLLinsleyPSHuangLYGermainRNShevachEM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression J Immunol. 1993151 122434 KawamuraTFurueM. Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines Eur J Immunol. 199525 19137 SchandeneLAlonso-VegaCWillemsFGerardCDelvauxAVeluT B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10 J Immunol. 1994152 436874 KitaniAFussINakamuraK Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis J Exp Med. 2003198 117988 BlaserKAkdisCA. Interleukin-10, T regulatory cells and specific allergy treatment Clin Exp Allergy. 200434 32831 KapsenbergML. Dendritic-cell control of pathogen-driven T-cell polarization Nat Rev Immunol. 20033 98493 BanchereauJSteinmanRM. Dendritic cells and the control of immunity Nature 1998392 24552 LutzMBSchulerG. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 200223 4459 DhodapkarMVSteinmanRMKrasovskyJMunzCBhardwajN. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells J Exp Med. 2001193 2338 JonuleitHSchmittESteinbrinkKEnkAH. Dendritic cells as a tool to induce anergic and regulatory T cells Trends Immunol. 200122 394400 BurklyLHessionCOgataLReillyCMarconiLAOlsonD Expression of relB is required for the development of thymic medulla and dendritic cells Nature 1995373 5316 MartinEO'SullivanBLowPThomasR. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 Immunity 200318 15567 AdoriniLPennaGGiarratanaNRoncariAAmuchasteguiSDanielKC Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands J Steroid Biochem Mol Biol. 200489–90 43741 de JongECVieiraPLKalinskiPKapsenbergML. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3 J Leukoc Biol. 199966 2014 LeeJIGansterRWGellerDABurckartGJThomsonAWLuL. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B Transplantation 199968 125563 DongXCraigTXingNBachmanLAPayaCVWeihF Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function J Biol Chem. 2003278 4937885 GregoriSCasoratiMAmuchasteguiSSmiroldoSDavalliAMAdoriniL. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance J Immunol. 2001167 194553 GregoriSGiarratanaNSmiroldoSUskokovicMAdoriniL. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice Diabetes 200251 136774 BelladonnaMLGrohmannUGuidettiPVolpiCBianchiRFiorettiMC Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO J Immunol. 2006177 1307 FallarinoFGrohmannUYouSMcGrathBCCavenerDRVaccaC The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells J Immunol. 2006176 675261 GrohmannUFallarinoFBianchiRBelladonnaMLVaccaCOrabonaC IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase J Immunol. 2001167 70814 MunnDHSharmaMDLeeJRJhaverKGJohnsonTSKeskinDB Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 2002297 186770 MunnDHZhouMAttwoodJTBondarevIConwaySJMarshallB Prevention of allogeneic fetal rejection by tryptophan catabolism Science 1998281 11913 GrohmannUOrabonaCFallarinoFVaccaCCalcinaroFFalorniA CTLA-4-Ig regulates tryptophan catabolism in vivo Nat Immunol. 20023 1097101 GrohmannUFallarinoFBianchiROrabonaCVaccaCFiorettiMC A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice J Exp Med. 2003198 15360 FallarinoFGrohmannUHwangKWOrabonaCVaccaCBianchiR Modulation of tryptophan catabolism by regulatory T cells Nat Immunol. 20034 120612 OrabonaCGrohmannUBelladonnaMLFallarinoFVaccaCBianchiR CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86 Nat Immunol. 20045 113442 FrumentoGRotondoRTonettiMDamonteGBenattiUFerraraGB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase J Exp Med. 2002196 45968 TernessPBauerTMRoseLDufterCWatzlikASimonH Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites J Exp Med. 2002196 44757 TaherYAPiavauxBJAGrasREschBCAMvHofmanGABloksmaN Indoleamine 2,3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model J Allergy Clin Immunol. 2008121 98391 BousquetJHejjaouiADhivertHClauzelAMMichelFB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. Systemic reactions during the rush protocol in patients suffering from asthma J Allergy Clin Immunol. 198983 797802 GreinederDK. Risk management in allergen immunotherapy J Allergy Clin Immunol. 199698 S3304 TaherYAvan EschBCHofmanGHenricksPAJVan OosterhoutAJ. 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta J Immunol. 2008180 521121